Skip to main content
Fig. 3 | Cardio-Oncology

Fig. 3

From: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study

Fig. 3

Estimates of association between baseline suPAR or serial suPAR measurements and the primary/secondary endpoints as markers of cardiotoxicity. Mixed effects linear regression was performed with adjustment for age, race/ethnicity, hypertension, dyslipidemia, diabetes, current smoker, body mass index, family history of premature ASCVD, aspirin, statin, ACE-i/ARB, and beta-blocker use

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us